YC W18
Macromoltek
Computational antibody design
About
Macromoltek: Revolutionizing antibody design. Description: Macromoltek, a computational de novo drug design company, rapidly produces accurate and credible antibody designs. We have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods and have are already designing antibodies for large biopharmas and smaller biotechs.
Founders
- Susana Kaufmann
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Macromoltek.
See family office activityIndustry & Focus
HealthcareDrug Discovery and DeliveryAI-powered Drug DiscoveryDeep LearningTherapeutics